Dr. Solange Peters showed 24-month overall survival rates were higher with tremelimumab, durvalumab, and chemotherapy versus chemotherapy alone across all subgroups, including those with KRAS, STK11, and KEAP1 mutations. Read more

In a Q&A with ILCN, Dr. Karen Kelly looks back at the moments that made lasting impressions and the presentations with the power to change the practice of thoracic oncology. Read more

Research presented during WCLC 2022 shows patient-centered summaries may help potential participants to better understand the benefits and risks of clinical trials. Read more

Experts evaluate available evidence comparing various strategies, including prophylactic cranial irradiation vs. surveillance, stereotactic radiosurgery vs. whole-brain radiotherapy, and more. Read more

Experts reviewed data that show smoking can reduce innate immunity and suppress the efficacy of anti-cancer agents, leading to poorer outcomes for patients who continue to smoke after their cancer diagnosis. Read more

The SHAWL study showed most women with lung cancer have little or no interest in sexual activity and experience increased pain and discomfort during sex following their diagnoses. Read more

Advances in radiotherapy, robotic surgery, and artificial intelligence promise to change the practice of thoracic oncology. Read more

Profession challenged to double survival rates within 5 years. Improving screening, reducing barriers to treatments will be key. Read more

During a WCLC 2022 education session, experts reviewed the evidence for multiple treatment strategies in various patient populations. Read more

A joint session at WCLC explored the impact the pandemic has had on the prevention, diagnosis, and management of thoracic malignancies. Read more